(Sharecast News) - Oxford Biomedica said that Sanofi's decision to terminate collaboration on a haemophilia treatment would have a "negligible" impact on revenue.
Sanofi had given notice to "terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat haemophilia", Oxford said on Friday.
"The group expects that the impact on revenue will be negligible over the coming 24 month period."
Oxford Biomedica (OXB)18 Jun 2024 16:37
EARNINGS AND TRADING: Cordel thrilled by Middle East contract win
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...